Skip to main content
2024 PharmSci 360 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Preclinical, Clinical and Translational Sciences
Prologue

Prologue: Biomarkers as Linkers Between Preclinical, Clinical, and Patient Outcome

On Demand
Location:Online Only

Preclinical & Translation Sciences

This short video will describe the role of biomarkers generally in drug development/clinical practice with the aim of covering the scope of their usage for assessing a variety of areas of pharmacological and clinical outcome. A brief introduction to PBPK modelling and how such frameworks have been used to assess ADME-related protein functional perturbations to assess DDI risk. I will also briefly cover the utility of genetic biomarkers for indicating immunogenicity risk. Finally, a short overview relating to AAV therapies and the translational challenges associated to developing such therapies for optimising dosing regimen.

To view all Prologues, visit our library here and click "Enroll".

Learning Objectives:

  • Upon completion, participant will be able to have a broad overview of the utility of biomarkers across biolgical disciplines
  • Upon completion, participant will be able to gain insignts into the utlity of biomarkers for assessing ADME protien function in DDI assessments
  • Upon completion, participant will recieve a high level summary of the key concepts of drug induced immunogenicity and challenges in translating pre-clinical studies to the clincial field, while cosnidering using biomarkers to assist in establishing immungenic risk.
  • Upon completion, participant will recieve a high level summary of the key concepts of challenges in predictions of pharmcokinetics or biodistribution of AAV gene therapies, where the presentation to be delivered at the meeting will provide perspectives on approaches to improvie PK-PD predicitions.
  • Upon completion, participant will have an undersatnding of the contents of the session entitled 'Biomarkers as Linkers Between Preclinical, Clinical, and Patient Outcome' that is to be delivered at the PharmSci360 meeting in October.